文献速递病毒性肝炎艾滋病与性传播感染

丙型肝炎病毒基因1型NS5A耐药相关变异与晚期肝纤维化相关且独立于HCV传播簇

Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
PubMed 文献 · Clin Microbiol Infect · 2018-07-05

该研究纳入387例未接受直接抗病毒治疗的基因1型HCV单纯感染及HIV/HCV合并感染患者,采用群体测序检测NS3/NS5A耐药相关变异。NS5A变异在晚期肝纤维化(F3-F4)和肝硬化(F4)患者中更常见,肝硬化与NS5A变异存在独立关联(OR 2.34,95%CI 1.004-5.291;P=0.049)。

要点

  • NS5A耐药相关变异在F3-F4患者中占17.17%(17/99),高于F0-F2的6.94%(17/245),P=0.004。
  • 肝硬化(F4)患者NS5A变异比值比为2.34(95%CI 1.004-5.291;P=0.049)。
  • NS5A变异在形成簇和成对的序列中较少见(5.16% vs 11.21%,P=0.039),提示为新发选择而非传播。

核心结论

  • NS5A耐药相关变异的存在与肝纤维化进展相关,代表变异的新发选择而非耐药传播。
  • NS5A耐药相关变异可能是长期HCV感染的预测指标。

研究设计与样本

  • 研究纳入387例未接受直接抗病毒治疗的基因1型HCV感染个体(54例基因1a型,333例基因1b型),包括HCV单纯感染和HIV/HCV合并感染者。
  • 采用群体测序鉴定NS3/NS5A耐药相关变异,肝纤维化依据组织病理学或超声弹性成像评估,使用最大似然模型鉴定系统发育簇。
  • 统计学方法包括卡方检验或双侧Fisher精确检验及多变量逻辑回归模型。

主要发现

  • NS3耐药相关变异在基因1a型中占33.33%(18/54),在基因1b型中占2.62%(8/297)。
  • NS5A变异在基因1a型中占5.55%(3/54),在基因1b型中占9.31%(31/333)。
  • NS5A第31和93密码子变异仅见于基因1b型:L31I/F/M占4.2%(14/333),Y93H占5.39%(17/333)。
  • NS5A耐药相关变异在晚期肝纤维化(F3-F4)中占17.17%(17/99),高于F0-F2的6.94%(17/245),P=0.004;在肝硬化(F4)中占20.34%(12/59),高于F0-F3的7.72%(22/285),P=0.003。
  • 肝硬化(F4)与HCV感染者中NS5A耐药相关变异的较高比值比相关(OR 2.34,95%CI 1.004-5.291;P=0.049)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of the study was to characterize the differences in the frequencies of NS3 and NS5A resistance-associated variants (RAVs) among Polish therapy-naive genotype 1 (G1) hepatitis C virus (HCV)-monoinfected and human immunodeficiency virus (HIV)/HCV-coinfected patients including clustering patterns and association of RAV frequency with liver fibrosis. METHODS: NS3/NS5A RAVs were identified by population sequencing in 387 directly acting antiviral treatment-naive G1-infected individuals (54 with genotype 1a (G1a) and 333 with genotype 1b (G1b)). Liver fibrosis was assessed based on histopathology or ultrasound elastography. Phylogenetic clusters were identified using maximum likelihood models. For statistics, chi-squared or two-sided Fisher's exact tests and multivariate logistic regression models were used, as appropriate. RESULTS: NS3 RAVs were found in 33.33% (18/54) for G1a and 2.62% (8/297) for G1b whereas NS5A variants were present in 5.55% (3/54) G1a and 9.31% (31/333) G1b sequences. Variations in NS5A 31 and 93 codon positions were found only in G1b (4.2% (14/333) for L31I/F/M and 5.39% (17/333) for Y93H). NS5A RAVs were more frequent among patients with advanced liver fibrosis (17.17% (17/99) for F3-F4 versus 6.94% (17/245) for F0-F2; p 0.004) or liver cirrhosis (20.34% (12/59) for F4 versus 7.72% (22/285) for F0-F3; p 0.003). Liver cirrhosis (F4) was associated with higher odds ratio of the NS5A RAVs among HCV-infected patients (odds ratio 2.34, 95% CI 1.004-5.291; p 0.049). NS5A RAVs were less frequent among sequences forming clusters and pairs (5.16% (8/155) versus 11.21% (26/232); p 0.039). CONCLUSIONS: Presence of NS5A RAVs correlated with progression of liver fibrosis and represents de novo selection of variants rather than transmission of drug resistance. Hence, the presence of NS5A RAVs may be a predictor for a long-lasting HCV infection.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Parczewski M, Kordek J, Janczewska E, et al. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters. Clin Microbiol Infect. 2018. PMID: 29981869. doi:10.1016/j.cmi.2018.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。